Proteomic biomarkers in lung cancer

• Autores: María Dolores Pastor Herrera, A. Nogal, Sonia Molina Pinelo, Amancio Carnero, Luis Paz-Ares Rodríguez
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 9, 2013, págs. 671-672
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The correct understanding of tumour development relies on the comprehensive study of proteins. They are the main orchestrators of vital processes, such as signalling pathways, which drive the carcinogenic process. Proteomic technologies can be applied to cancer research to detect differential protein expression and to assess different responses to treatment. Lung cancer is the number one cause of cancer-related death in the world. Mostly diagnosed at late stages of the disease, lung cancer has one of the lowest 5-year survival rates at 15 %. The use of different proteomic techniques such as two-dimensional gel electrophoresis (2D-PAGE), isotope labelling (ICAT, SILAC, iTRAQ) and mass spectrometry may yield new knowledge on the underlying biology of lung cancer and also allow the development of new early detection tests and the identification of changes in the cancer protein network that are associated with prognosis and drug resistance.